|
Marc A. Rubenstein
Partner
|
|
|
|
Marc Rubenstein, co-chair of the Life Sciences Practice Group, focuses on representing clients in the biotechnology, medical device and pharmaceutical industries in a wide variety of transactions, including license and collaboration agreements, public and private securities offerings and mergers and acquisitions. He has extensive experience representing life sciences clients in structuring and negotiating collaborative research, development and licensing arrangements. In these transactions, Marc has represented both licensors and licensees, and has negotiated early and late stage product agreements and platform and drug discovery deals. In addition, he has broad experience negotiating supply and manufacturing agreements, distribution and co-promotion agreements, university license agreements, sponsored research agreements and other commercial agreements that arise regularly in the life sciences industry.
Marc regularly represents publicly traded life sciences companies in securities matters, including IPOs, PIPEs, standby equity lines, at-the-market offerings and other types of financings, as well as advising these companies in ongoing reporting matters. He also represents venture-backed life sciences companies in financings and ongoing matters, and has extensive experience advising public and private life sciences companies in mergers and acquisitions, including tender offers, mergers and asset acquisitions and sales.
Before joining Ropes & Gray in 2001, Marc was a partner at Palmer & Dodge in the Life Sciences and Technology Group.
- Represented Sirtris Pharmaceuticals from inception, through its venture financings and IPO, and in its subsequent sale to GlaxoSmithKline for $720 million.
- Represented Biogen Idec in a number of licensing agreements and other transactions, including the acquisition of certain assets of Nerimmune for an upfront payment of $32.5 million and up to $395 million in contingent payments.
- Represented Stryker Corp. in the sale of its bone growth therapies product line, including OP-1 Implant, OP-1 Putty, Opgenra and Osigraft, to Olympus for $60 million.
- Represented Ironwood Pharmaceuticals in developing and implementing its worldwide licensing strategy for linaclotide, including licensing linaclotide to Forest Laboratories, Laboratorios Almirall and Astellas Pharma with aggregate upfront payments of $140 million.
- Represented Merck & Co. in its acquisition of Hawaii Biotech's dengue fever vaccine research unit out of bankruptcy.
- Represented Acceleron Pharma in its venture financings and other transactions, including its:
- ex-North American collaboration and licensing agreement with Shire Pharmaceuticals for Acceleron’s ActRIIB products, including an upfront payment to Acceleron of $45 million.
- collaboration and licensing agreement with Celgene, including an upfront payment to Acceleron of $50 million and a $5 million equity investment.
- Represented Forest Laboratories in a license agreement with TransTech Pharma regarding the development and commercialization of glucokinase activators.
- Represented RXi Pharmaceuticals in a PIPE financing, two registered direct offerings and the establishment of a standby equity line.
Honors & Awards
- Chambers USA: America's Leading Lawyers for Business (2009-2012)
- The Best Lawyers in America (2009-2011)
Professional & Civic Activities
Marc regularly contributes to a variety of publications on corporate and licensing law matters, and has also been a faculty member of CLE programs on these topics. He is a member of the Board of Overseers of the Boston Museum of Science and of Combined Jewish Philanthropies of Greater Boston, where he currently co-chairs the Supplementary Education Task Force and serves on the Innovations Grant Committee. Marc also dedicates his time to serving on the Board of Trustees and Executive Committee of Jewish Big Brothers Big Sisters of Greater Boston.
©1996-2012 Ropes & Gray LLP. All rights reserved.
|
|
Education
-
JD, cum laude, Cornell Law School, 1989; Note Editor, Cornell International Law Journal, Editor, 1989 Symposium Issue, Harvard Journal of Law and Public Policy
-
BA, Cornell University, 1986
|
|